Fat around your middle is better than BMI for predicting the risk to your heart

Publicly released:
International
CC:0
CC:0

US researchers say fat around your tummy is a better indicator of your risk of developing cardiovascular disease than using your BMI alone. The team looked at data from over 260,000 people over an average of 20 years, who had either their waist circumference or waist-to-hip ratio measured, and had at least one instance of nine heart-related issues - such as heart attack, stroke and heart or cardiovascular disease. The researchers say that, in people with 'normal' weight as determined by their BMI, 5% had a high waist circumference and 18% had a high waist-to-hip ratio. In these people, the researchers say they found a link to a 15-50% higher risk of the nine heart issues. Additionally, the researchers say the people with obesity as defined by their BMI but a low waist circumference were not linked to a significantly different risk of heart issues, compared with those who had normal weight and low waist circumference.

News release

From: American College of Cardiology

Abdominal Fat Predicts Heart Disease Risk Better Than BMI

Study shows BMI does not reflect overall body composition since central adiposity is not measured

WASHINGTON (August 11, 2026) —The size of a person’s midsection is a better indicator of cardiovascular disease risk when compared to their body mass index (BMI) alone, according to a study published in JACC, the flagship journal of the American College of Cardiology. BMI has traditionally been used to determine overweight or obesity, common risk factors for heart disease, but this study shows that not accounting for waist circumference (WC) or waist-to-hip ratio (WHR) can lead to misclassification of cardiovascular disease risk.

“Indeed, it appears that WC and WHR reclassify risk defined by traditional BMI thresholds,” said Michael J. Blaha, MD, MPH, senior author of the study and director of clinical research at Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. “We saw individuals with clinically determined normal weight who had elevated central adiposity and high WHR, associating them with higher risk across most outcomes.”

BMI is calculated by dividing weight in kilograms by height in meters squared and is a common practice for diagnosing obesity. However, BMI cannot account for distribution of body fat. Studies have shown that visceral fat, which is fat that surrounds the internal organs in the abdominal area, is associated with chronic diseases like heart disease and diabetes, while subcutaneous fat, which is located directly under the skin, is not as strongly associated.

Despite evidence linking central adiposity, the accumulation of both visceral and subcutaneous fat in the abdominal area, to adverse cardiovascular health outcomes, BMI is still the most used metric to determine overweight and obesity and future cardiovascular risk.

This study examines whether adding WC and WHR to BMI better predicts future cardiovascular risk. Researchers from the Cross Cohort Collaboration looked at over 260,000 people over an average of 20 years who had either WC or WHR data and at least one of nine outcomes: time to first fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, heart failure, atrial fibrillation, total coronary heart disease (CHD), total cardiovascular disease (CVD), CHD mortality, CVD mortality and/or all-cause mortality.

In individuals with normal weight as determined by BMI, 5% had high WC and 18% had high WHR; among those with overweight, 39% had high WC and 40% had high WHR. Among those with obesity, 9% had low WC and 45% had low WHR.

Those individuals with normal weight or overweight and clinically defined high WC or WHR were associated with a 15% - 50% greater risk for most of the nine studied outcomes. Those with obesity and low WC were not found to be associated with a significantly different risk of outcomes compared with those who had normal weight and low WC, except for all-cause mortality, for which risk was significantly lower.

“Our findings emphasize the critical role of identifying elevated central adiposity, even in individuals with a normal BMI or with a BMI in the overweight range. Relying solely on BMI may result in misclassification of cardiovascular risk across a wide range of cardiovascular outcomes,” Zeina A. Dardari, PhD, MS, lead author of the study, said. “We encourage clinicians to consider central adiposity distribution across the entire BMI spectrum when evaluating cardiovascular risk in primary prevention settings.”

Limitations of the study include that it did not have measures of physical activity, diet or genetic obesity risk, which have all been shown to play a role in the development of CVD. It also included only one assessment of WC and WHR, which could limit understanding of how changes in central fat accumulation over time influences CVD risk.

“It is time to abandon a sole focus on body mass index,” said Harlan M. Krumholz, MD, FACC, Editor-in-Chief of JACC and the Harold H. Hines, Jr Professor at the Yale School of Medicine. “This enormously important study, based on data from hundreds of thousands of participants in large-scale cohort studies, authoritatively shows that waist circumference and waist-to-hip ratio provide critical information about cardiovascular risk, even among people with a BMI considered normal. Where fat is distributed matters, and these simple measures should be part of routine cardiovascular risk assessment.”

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research American College of Cardiology, Web page The URL will go live after the embargo ends
Journal/
conference:
JACC
Research:Paper
Organisation/s: Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, USA
Funder: The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Department of Health and Human Services, under Contract nos. 75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, and 75N92022D00005. The CARDIA Study is con- ducted and supported by the NHLBI in collaboration with the Uni- versity of Alabama at Birmingham (75N92023D00002 and 75N92023D00005), Northwestern University (75N92023D00004), University of Minnesota (75N92023D00006), and Kaiser Foundation Research Institute (75N92023D00003). This Cardiovascular Health Study research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and 75N92021D00006; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, U01HL130114, and R01HL172803, with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR000003, Johns Hopkins Uni- versity UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH road- map for Medical Research, Michigan Institute for Clinical and Health Research UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/ NCRR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. A portion of the data reported here have been supplied by the U.S. Renal Data System. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. The DHS was supported by grants from the Donald W. Reynolds Foundation and the National Center for Advancing Translational Sci- ences (UL1TR001105). The Brazilian Longitudinal Study of Adult Health baseline study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Min- istry of Science and Technology (Financiadora de Estudos e Projetos and CNPq National Research Council) (grants 01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ). The Framingham Heart Study is supported by con- tracts NO1-HC-25195, HHSN268201500001I, and 75N92019D00031 from the NHLBI. The JHS is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo Col- lege (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Med- ical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities. The MESA study was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01- HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the NHLBI, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the NCATS. The Rancho Bernardo Study was funded by research grants AG028507 and AG07181 from the NIA and grant DK31801 from the National Institute of Diabetes and Digestive and Kidney Diseases. The REGARDS Study is supported by cooperative agreement U01 NS041588 cofunded by the NINDS and the NIA, NIH, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis, or interpretation of the data. The Strong Heart Study has been funded in whole or in part with federal funds from the NHLBI, NIH, Department of Health and Human Services, under contract numbers 75N92019D00027, 75N92019D00028, 75N92019D00029, and 75N92019D00030. The study was previously supported by research grants R01HL109315, R01HL109301, R01HL109284, R01HL109282, and R01HL109319 and by cooperative agreements U01HL41642, U01HL41652, U01HL41654, U01HL65520, and U01HL65521. The Study of Osteoporotic Fractures is supported by NIH funding. The NIA provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The SWAN has grant support from the NIH, DHHS, through the NIA, the National Institute of Nursing Research, and the NIH Office of Research on Women’s Health (grants U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG 012553, U01AG012554, U01AG012495, and U19AG063720), and The SWAN Repository (U01AG017719). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, National Institute of Nursing Research, Office of Research on Women’s Health, or the NIH. The Women’s Health Initiative program is funded by the NHLBI, NIH, U.S. Depart- ment of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. Dr Blaha has served on advisory board for Novo Nordisk, Bayer, Eli Lilly, Astra- Zeneca, Boehringer Ingelheim, Genentech, Idorsia, Agepha, Vectura, and New Amsterdam. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Media Contact/s
Contact details are only visible to registered journalists.